All In Biotech

Drug Trial Radar · NCT06194552

A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07

A Multiple Ascending Dose, Phase 1, Double-Blind, Study to Investigate the Safety and Pharmacokinetics of NTRX-07 in Healthy Volunteers and Patients With Early Alzheimer's Disease (AD), With an Exploratory Fed-Fasted Assessment

Last checked: Nov 19, 2026Latest source record: Jan 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Sep 6, 2022

Primary completion

May 31, 2023

Study completion Jun 30, 2023

Sponsor

Lead sponsor
NeuroTherapia, Inc.Industry
Sponsor type
Industry
Collaborators
CRU Early Phase Unit Kistarcsa
First posted
Jan 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Multiple Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers and Subjects with MCI or Early AD. In addition, an exploratory study of the effect of a high fat meal was conducted.

Conditions

  • Alzheimer Disease

Interventions

  • NTRX-07Drug

    Investigational orally administered CB2 agonist

  • PlaceboDrug

    Matched placebo administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Related Adverse EventsTime frame: From admission to discharge, up to 2 weeks

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • NeuroTherapia

    Gates Mills, Ohio

  • CRU Early Phase Unit Kistarcsa

    Kistarcsa, Hungary

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.